-
公开(公告)号:US10578607B2
公开(公告)日:2020-03-03
申请号:US15817431
申请日:2017-11-20
申请人: Min-Hsien Wu , Wen-Pin Chou , Tzu-Keng Chiu , Po-Yu Chu
发明人: Min-Hsien Wu , Wen-Pin Chou , Tzu-Keng Chiu , Po-Yu Chu
IPC分类号: G01N33/49 , C12N5/09 , G01N27/327 , G01N33/574 , G01N27/447 , C12N13/00
摘要: A method of screening, isolating and purifying rare cells includes obtaining cell groups with rare cells from a sample, removing cells not to be screened from the cell groups, and drawing the remaining cells as a cell suspension sample. An introduction device is activated to load the cell suspension sample onto an optically-induced dielectrophoresis chip including a cell isolation zone having a division arrangement wherein at least one optical pattern is configured on the cell isolation zone for screening, isolating and purifying the rare cells. The at least one optical pattern is configured to migrate, rotate or both. The at least one optical pattern is activated to attract the rare cells into a collection tank on the chip, and a liquid drawing device is activated to draw the rare cells out of the collection tank, thereby obtaining purified rare cells from the sample.
-
公开(公告)号:US20200064333A1
公开(公告)日:2020-02-27
申请号:US16422045
申请日:2019-05-24
发明人: Mallikarjun SUNDARAM , Pradip MAJUMDER , Biswanath MAJUMDER , Misti JAIN , Saravanan THIAGARAJAN , Dency PINTO , Padhma RADHAKRISHNAN
IPC分类号: G01N33/50 , G01N33/574 , C12Q1/6886 , C12N5/09
摘要: The present disclosure relates to an Extra Cellular Matrix composition specific for cancer type and a tumor microenvironment platform for long term culturing of tumor tissue, wherein said culturing provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems. The present disclosure further relates to the development of a Clinical Response Predictor and its application in the prognostic field (selection of treatment option for the patient) and translational biology field (development of anticancer drugs). The disclosure further relates to a method of predicting clinical response of a tumor patient to drug(s). The disclosure further relates to a method for screening tumor cells for the presence of specific markers for determining the viability of said cells for indication of tumor status.
-
公开(公告)号:US20200063108A1
公开(公告)日:2020-02-27
申请号:US16489142
申请日:2018-02-28
摘要: The present invention provides methods of three dimensional tissue cultures and methods of using same.
-
公开(公告)号:US20200033345A1
公开(公告)日:2020-01-30
申请号:US16491187
申请日:2018-03-06
申请人: Natalia MALARA , Vincenzo MOLLACE
发明人: Natalia MALARA
IPC分类号: G01N33/574 , C12N5/09 , G01N33/50
摘要: The present invention relates to an in vitro method for the diagnosis and/or prognosis of non-haematological tumours by analysing circulating tumour cells isolated from a blood sample or a derivative thereof and to a kit for such purpose. The present invention further relates to a specific culture medium particularly effective for use in such method.
-
公开(公告)号:US20200010809A1
公开(公告)日:2020-01-09
申请号:US16282815
申请日:2019-02-22
申请人: HemoShear, LLC
发明人: Brian R. Wamhoff , Brett R. Blackman , Robert A. Figler , Daniel G. Gioeli , Michael B. Simmers
摘要: Methods for mimicking a tumor microenvironment in vitro are provided. The methods comprise indirectly applying a shear stress upon at least one tumor cell type plated on a surface within a cell culture container. Methods for mimicking tumor metastasis and methods for testing drugs or compounds in such systems are also provided.
-
公开(公告)号:US10472598B2
公开(公告)日:2019-11-12
申请号:US15310224
申请日:2015-05-20
发明人: Ryohei Tsukada , Haruo Okubo
摘要: A cell aggregate culture vessel (1) is a vessel for culturing a cell aggregate. The cell aggregate culture vessel (1) includes a well (21) having a culture space capable of storing the cell aggregate and culture fluid and a tubular body (3) which is disposed on the well on a plane at which the well has an opening and have an inner cavity communicating with the culture space, and one or more communication portion (3a) capable of discharging the culture fluid without allowing passage of the cell aggregate to the outside of the tubular body (3) is formed in a tubular wall of the tubular body (3). The communication portion (3a) may be, for example, a slit having a width of 0.1 mm or larger and 0.5 mm or smaller.
-
公开(公告)号:US10465168B2
公开(公告)日:2019-11-05
申请号:US14780002
申请日:2015-04-30
发明人: Yoon-Kyoung Cho , Tae-Hyeong Kim
摘要: A particle filtering device which shortens the separation time of particles and increases the separation efficiency are provided. The particle filtering device comprises: a filtration membrane which separates a particle by filtering a sample; a first body connected to an inlet side of the filtration membrane, which supplies the sample to the inlet side of the filtration membrane; and a second body connected to an outlet side of the filtration membrane, which accommodates a permeate whose particle is separated through the filtration membrane, wherein the particle filtering device has a structure in which the permeate is accommodated in advance between the second body and the outlet side of the filtration membrane.
-
公开(公告)号:US10463764B2
公开(公告)日:2019-11-05
申请号:US15585653
申请日:2017-05-03
IPC分类号: C12N5/074 , C12N5/0775 , A61L27/38 , A61L27/22 , G01N33/50 , C12N5/077 , C12N5/09 , A61L27/54 , A61L27/36
摘要: A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
-
公开(公告)号:US10457943B2
公开(公告)日:2019-10-29
申请号:US15826535
申请日:2017-11-29
IPC分类号: A61K48/00 , C07H21/04 , C12N15/113 , A61K31/7088 , A61K45/06 , A61K31/7105 , C12N5/09
摘要: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).
-
公开(公告)号:US20190300832A1
公开(公告)日:2019-10-03
申请号:US16029680
申请日:2018-07-09
发明人: Peng-Yuan Wang , Yin-Ju Chen , Long-Sheng Lu , Thierry Burnouf
摘要: A method for expanding circulating tumor cell in vitro includes preparing a cell culture tool having a multi-particle colloidal crystal layer, preparing a cell solution including circulating tumor cells, and contacting the cell solution with the multi-particle colloidal crystal layer, to attach the circulating tumor cells in the cell solution to the multi-particle colloidal crystal layer and rapidly expand by 20 times or more. The multi-particle colloidal crystal layer at least includes first particles having a particle size of 1000 to 5000 nm and second particles having a particle size of 20 to 400 nm. The culture medium in the cell solution at least includes a platelet lysate.
-
-
-
-
-
-
-
-
-